A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 731 participants.

Also called NCT06610526

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 731 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06610526
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06610526. Non-randomized; no masking; primary purpose treatment. Start 2024-08-23 (actual); primary completion 2027-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
Intervention (Drug)
Dapagliflozin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct06610526
Content hash
c2c46ba18c8f3f344cc27fca396d9976cbde756b0defd12691bf651e02c8226a